VETC is an Effective Marker for Postoperative Adjuvant Immunotherapy
NCT06253364
·
clinicaltrials.gov ↗
COMPLETED
Status
462
Enrollment
OTHER
Sponsor class
Conditions
HCC
Recurrence
Interventions
DRUG:
PD-1 monoclonal antibody and lenvatinib
Sponsor
Chen Xiaoping